687P - Synuclein-gamma (SNCG) predicts poor clinical outcome in esophageal cancer patients

Date 29 September 2014
Event ESMO 2014
Session Poster Display session
Topics Oesophageal Cancer
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Didem Tastekin
Citation Annals of Oncology (2014) 25 (suppl_4): iv210-iv253. 10.1093/annonc/mdu334
Authors D. Tastekin1, K. Erturk2, M. Tambas3, S. Karabulut4, D. Duranyıldız5, K. Kilic6, F. Tas7
  • 1Medical Oncology, Institute of Oncology, University of Istanbul, 34000 - ISTANBUL/TR
  • 2Department Of Medical Oncology, Istanbul University Institute of Oncology, 34093 - Istanbul/TR
  • 3Department Of Radiation Oncology, Istanbul University, Istanbul Faculty of Medicine, 34093 - ISTANBUL/TR
  • 4Medical Oncology, Institute of Oncology, University of Istanbul, ISTANBUL/TR
  • 5Basıc Oncology, Institute of Oncology, University of Istanbul, ISTANBUL/TR
  • 6Department Of General Surgery, Kartal Educational and Research Hospital, Istanbul, Turkey, 34093 - ISTANBUL/TR
  • 7Medical Oncology, Istanbul University, Institute of Oncology, ISTANBUL/TR



Esophageal cancer (EC) is a rare tumor with poor prognosis due to diagnosis at advanced stage and lack in high sensitive and specific markers which can detect the disease at earlier stages. The aim of our study was to evaluate the immunohistochemical (IHC) expression of synuclein-gamma (SNCG) in correlation with its association with clinicopathological parameters and prognostic value in EC patients.


SNCG levels were assessed with IHC methods in cancer tissues from 73 patients with EC. The intensity and area of the IHC reactions were evaluated using the semi-quantitative scoring system.


Median age was 57 (range, 29-78) years old. Forty-seven percent of the patients were male. Thirty-seven percent of the patients had upper or middle localized tumor whereas 59% had epidermoid carcinoma. More than half of the patients (61%) had undergone operation where 57% received adjuvant treatment (chemotherapy or chemoradiotherapy). Median overall survival was 11.3 ± 1.8 months (95%CI: 7.7-14.9 months). SNCG positivity was significantly associated with the histological type of EC and inoperability (for SNCG positive vs. negative group; epidermoid 80% vs. 53%; p = 0.05 and inoperable 59% vs.32%; p = 0.04, respectively). Lymph node metastasis, inoperability and receiving no adjuvant treatment had significantly adverse effect on survival in the univariate analysis (p = 0.01, p < 0.001 and p = 0.001, respectively). SNCG positivity had significantly adverse effect on survival in both univariate and multivariate analysis (p = 0.02 and p = 0.01 respectively).


Our results are the first to suggest that SNCG is a new independent predictor for poor prognosis in EC patients in the literature.


All authors have declared no conflicts of interest.